全球人工器官和仿生植入市場規模（植入類型、應用、最終用戶、區域範圍和預測）

人工器官及仿生植入市場規模及預測

預計2024年人工器官和仿生植入市場規模將達375.6億美元，2031年將達到776.3億美元，2024年至2031年的複合年成長率為9.5%。

人工器官和仿生植入是模仿受損或切除的自然器官或身體部位功能的醫療設備。人工器官，例如心臟瓣膜、腎臟和肺，旨在取代衰竭的器官；而仿生植入，例如義肢和仿生眼，則可改善或恢復感覺或運動功能。這些器械對於治療器官衰竭、截肢和感覺障礙患者至關重要，它們在提供挽救生命的干涉措施的同時，也能顯著改善生活品質。材料科學、生物工程和機器人技術的進步正在催生出越來越複雜和實用的解決方案，例如完全可植入的人工心臟和具有接近自然靈活性的先進義肢。

生物技術和材料科學的持續進步有望推動人造器官和仿生植入取得重大進展。 3D列印、幹細胞研究和奈米技術等新興技術有望幫助創造更個人化和功能性的植入。例如，利用患者自身細胞進行生物列印器官最終可以解決器官排斥和器官短缺的問題。

此外，人工智慧和機器學習的融合有望提升仿生設備的適應性和效用，為消費者提供更直覺、更快速的解決方案。隨著這些技術的發展，它們有望顯著擴大可治療疾病的範圍，並改善複雜醫療需求患者的治療效果，從而使人工器官和仿生植入成為未來醫療創新的重點。

全球人工器官與仿生植入市場動態

影響全球人工器官和仿生植入市場的關鍵市場動態是：

主要市場促進因素：

器官衰竭和慢性疾病盛行率上升：器官衰竭和慢性疾病盛行率上升是人工器官和仿生植入市場的主要驅動力。截至2021年1月，器官共享聯合網路（UNOS）報告稱，僅在美國，就有超過10.7萬人在器官移植等候名單上。器官需求與供應之間的巨大差距正在推動人工器官和仿生植入的開發和應用。

全球人口老化：全球人口老化正在推動市場成長。世界衛生組織 (WHO) 預測，到 2050 年，全球 60 歲以上人口比例將幾乎加倍，從 12% 增加到 22%。隨著人口老化加劇，與老齡化相關的器官衰竭和體弱的盛行率也將上升，從而催生對人工器官和仿生植入的需求。

生物工程和材料科學的技術進步：生物工程、材料科學和奈米技術的快速發展使得人們能夠創造出更複雜、更有效的人造器官和仿生植入。例如，美國國家醫療圖像和生物工程研究所 (NIBIB) 在 2020 年報告稱，研究人員創造了一種新的人造心臟，其結構更接近真實人類心臟，有可能改善等待心臟移植的患者的預後。

醫療支出成長和報銷政策優惠：已開發國家醫療成本的上漲和報銷系統的完善，正在推動人工器官和仿生植入產業的發展。根據美國醫療保險和醫療補助服務中心 (CMS) 的數據，預計到 2020 年，美國醫療支出將增加 9.7%，達到 4.1 兆美元，即人均 12,530 美元。支出的成長，加上複雜醫療技術的保險覆蓋範圍不斷擴大，使得人工器官和仿生植入的普及率得以提升。

主要挑戰

高成本：開發和製造人造器官和仿生植入需要大量的研發和生產資源。這些高成本往往會增加病患的負擔，並可能限制其可近性和普及性，尤其是在開發中國家和健保不足的國家。

監管障礙：由於監管嚴格，人造器官和仿生植入的核准流程複雜且耗時。滿足這些標準需要大量的臨床試驗和文件記錄，這可能會延遲產品進入市場並增加公司成本。

併發症：植入人工器官和仿生裝置會增加感染疾病、裝置故障和不良反應的風險。這些風險需要持續監測，並可能涉及進一步的手術或干涉，從而影響患者的安全和預後。

患者適應：患者很難適應人造器官和仿生植入，通常需要醫療保健專業人員的大量培訓和支持才能成功地將它們融入日常生活。

主要趨勢：

生物材料的進步：生物相容性聚合物和複合陶瓷等新型生物材料的開發，提高了人工器官和仿生植入的功能和壽命。這些材料能夠更好地與人體結合，並降低排斥反應和出現問題的可能性。

整合人工智慧和機器學習：人工智慧和機器學習正在迅速用於改善仿生植入物的功能。人工智慧演算法可以提高設備效能，增強用戶體驗，並允許根據患者的特定需求進行即時修改。

3D 生物列印：3D 生物列印技術有望改變人造器官的製造方式，它能夠利用患者特異性細胞創建先進的個人化組織和器官，從而有可能改善患者的治療效果，同時縮短器官移植的等待時間。

個人化醫療：個人化醫療提倡根據特定患者的情況客製化人工器官和仿生植入，根據每個患者的遺傳、生理和生活方式特徵量身定做設備，以改善性能和結果。

目錄

第1章 引言

• 市場定義
• 市場區隔
• 調查方法

第2章執行摘要

• 主要發現
• 市場概況
• 市場亮點

第3章 市場概況

• 市場規模和成長潛力
• 市場趨勢
• 市場促進因素
• 市場限制
• 市場機遇
• 波特五力分析

4. 人造器官和仿生植入市場（依植入類型）

• 人造器官
• 仿生植入

5. 人造器官和仿生植入市場（依應用）

• 心血管植入
• 整形外科植入
• 神經系統植入
• 眼科植入
• 器官移植

第6章 區域分析

• 北美洲
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東和非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合大公國

第7章市場動態

• 市場促進因素
• 市場限制
• 市場機遇
• COVID-19 市場影響

第8章 競爭態勢

• 主要企業
• 市佔率分析

第9章：公司簡介

• Abbott Laboratories
• Medtronic
• Johnson & Johnson
• Siemens Healthineers
• Stryker Corporation
• Zimmer Biomet
• B. Braun Melsungen
• Edwards Lifesciences
• Boston Scientific
• Organovo Inc.

第10章：市場展望與機遇

• 新興技術
• 未來市場趨勢
• 投資機會

第11章 市場展望 附錄

• 簡稱列表
• 來源和參考文獻

Artificial Organ And Bionic Implants Market Size And Forecast

Artificial Organ And Bionic Implants Market size was valued at USD 37.56 Billion in 2024 and is projected to reach USD 77.63 Billion by 2031, growing at a CAGR of 9.5% from 2024 to 2031.

Artificial organs and bionic implants are medical devices that mimic the functions of natural organs or body components that are damaged or removed. Artificial organs, such as heart valves, kidneys, and lungs, are designed to perform the duties of failing organs, whereas bionic implants, such as prosthetic limbs or bionic eyes, improve or restore sensory and motor functions. These devices are essential for treating patients with organ failure, amputations, or sensory impairments, as they provide life-saving interventions while also significantly improving the quality of life. Advances in materials science, bioengineering, and robotics have resulted in increasingly sophisticated and practical solutions, including fully implantable artificial hearts and advanced prosthetic limbs with near-natural dexterity.

Artificial organs and bionic implants are set for significant expansion, thanks to continued advances in biotechnology and materials science. Emerging technologies such as 3D printing, stem cell research, and nanotechnology are expected to help create more individualized and functional implants. For instance, bioprinting organs from a patient's cells could ultimately solve organ rejection and shortages.

Furthermore, the integration of artificial intelligence and machine learning is expected to improve the adaptability and usefulness of bionic devices, resulting in more intuitive and responsive solutions for consumers. As these technologies evolve, the potential for significantly broadening the range of treatable illnesses and improving outcomes for people with complicated medical demands grows, making artificial organs and bionic implants a key focus of future medical innovation.

Global Artificial Organ And Bionic Implants Market Dynamics

The key market dynamics that are shaping the global artificial organ and bionic implants market include:

Key Market Drivers:

Increasing Prevalence of Organ Failure and Chronic Diseases: The rising prevalence of organ failure and chronic diseases is a significant driver of the artificial organ and bionic implants market. As of January 2021, the United Network for Organ Sharing (UNOS) reported that there were over 107,000 persons on the national transplant waiting list in the United States alone. The significant gap between organ demand and availability is driving the development and use of artificial organs and bionic implants.

Aging Population Worldwide: The world's aging population is driving market growth. The World Health Organization (WHO) predicts that by 2050, the proportion of the world's population aged 60 and up will nearly double from 12% to 22%. As the aged population grows, so does the prevalence of age-related organ failures and infirmities, creating a demand for artificial organs and bionic implants.

Technological Advancements in Bioengineering and Materials Science: Rapid progress in bioengineering, materials science, and nanotechnology is allowing for the creation of more sophisticated and effective artificial organs and bionic implants. For instance, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) reported in 2020 that researchers created a new artificial heart that more closely resembles the structure of a real human heart than ever before, potentially improving outcomes for patients awaiting heart transplantation.

Increasing Healthcare Expenditure and Favorable Reimbursement Policies: Rising healthcare costs and improved reimbursement scenarios in developed nations are driving the artificial organ and bionic implant industry. According to the Centers for Medicare & Medicaid Services (CMS), U.S. national health spending will increase by 9.7% to $4.1 trillion in 2020, or $12,530 per person. This increased spending, combined with expanded insurance coverage for complex medical technologies, is allowing for broader access to artificial organs and bionic implants.

Key Challenges:

High Costs: Creating and manufacturing artificial organs and bionic implants requires enormous research, development, and production resources. This high cost frequently results in increased rates for patients, which can limit accessibility and uptake, particularly in developing countries or for those without complete insurance coverage.

Regulatory Hurdles: Due to severe regulatory regulations, the approval process for artificial organs and bionic implants is complex and time-consuming. Meeting these criteria necessitates substantial clinical trials and documentation, which can delay market access and increase businesses' expenses.

Complications: Implanting artificial organs and bionic devices increases the risk of infections, device failures, and bad responses. These risks demand ongoing monitoring and may entail further operations or interventions, affecting patient safety and outcomes.

Patient Adaptation: Patients may struggle to adjust to artificial organs or bionic implants, especially when the devices require considerable behavioral or lifestyle changes. Successful incorporation into daily life frequently necessitates substantial training and support from healthcare professionals.

Key Trends:

Biomaterials advancements: The development of new biomaterials, such as biocompatible polymers and complex ceramics, improves the functionality and lifetime of artificial organs and bionic implants. These materials increase integration with the human body and lower the likelihood of rejection or problems.

Integration of AI and Machine Learning: Artificial intelligence and machine learning are rapidly being used in bionic implants to improve their functionality. AI-powered algorithms can improve device performance, enhance user experience, and allow for real-time modifications depending on unique patient needs.

3D Bioprinting: 3D bioprinting technology is changing the way artificial organs are made by allowing sophisticated, personalized tissues and organs to be created from patient-specific cells. This device has the potential to shorten organ transplant waiting times while improving patient outcomes.

Personalized Medicine: Personalized medicine is driving the customization of artificial organs and bionic implants to meet specific patient profiles. Tailoring devices to each patient's genetic, physiological, and lifestyle characteristics can result in enhanced performance and outcomes.

Global Artificial Organ And Bionic Implants Market Regional Analysis

Here is a more detailed regional analysis of the global artificial organ and bionic implants market:

North America:

North America dominates the global artificial organ and bionic implants market owing to its advanced healthcare infrastructure, robust research and development ecosystem, and a large pool of skilled workers. This dominance is strengthened by the existence of significant medical device and biotechnology businesses, as well as a favorable regulatory environment. The increasing frequency of chronic diseases, such as end-stage renal disease (ESRD), which affects over 786,000 Americans and is expected to reach 971,000 by 2030, is boosting demand for artificial kidneys and renal replacement therapy. The aging population, with all baby boomers predicted to be over 65 by 2030, increases the demand for artificial organs and bionic implants to treat age-related organ failure and disability.

The National Institute of Biomedical Imaging and Bioengineering (NIBIB) has developed a new artificial pancreas technology, which is boosting market growth. This technology, which automates blood glucose monitoring and insulin delivery, marks a significant advancement in diabetes management. Furthermore, growing healthcare spending, which the Centers for Medicare and Medicaid Services (CMS) predicts will reach USD 6.2 Trillion by 2028, is increasing access to this breakthrough technology. This investment is likely to drive additional innovation and adoption of artificial organs and bionic implants, cementing North America's market supremacy.

Asia Pacific:

The Asia-Pacific area is rapidly expanding its artificial organ and bionic implants market, emerging as the world's fastest-growing sector. Several factors contribute to this expansion, including an expanding population, rising healthcare costs, and increased knowledge of new medical technologies. Significant expenditures in healthcare infrastructure and research are pushing the region's growth and establishing it as a major participant in the worldwide market. The increased incidence of chronic diseases, particularly diabetes, with 206 million adults affected in 2021 and an estimated 260 million by 2045, is driving strong demand for artificial pancreas systems and related technologies.

The increasingly aging population contributes to market growth, with the number of people over 65 in Asia and the Pacific predicted to more than quadruple from 630 million in 2020 to 1.3 billion by 2050. This demographic transition increases the demand for artificial organs and bionic implants to address age-related health concerns. Technological advancements, such as the Japan Agency for Medical Research and Development (AMED) development of a fully implantable artificial heart, as well as increased healthcare spending, which is expected to grow at a 5.2% annual rate in the Western Pacific Region from 2020 to 2024, are also driving market growth. These aspects, taken together, contribute to the rapid growth and innovation of the Asia-Pacific artificial organ and bionic implants market.

Global Artificial Organ And Bionic Implants Market: Segmentation Analysis

The Global Artificial Organ And Bionic Implants Market is Segmented on the basis of Type of Implant, Application, End-User, And Geography.

Artificial Organ And Bionic Implants Market, By Type of Implant

Artificial Organs

Bionic Implants

Based on Type of Implant, the market is fragmented into Artificial Organs and Bionic Implants. While bionic implants are currently leading the artificial organ and bionic implants market due to their growing applications in domains such as vision, hearing, and orthopedics, artificial organs are expanding the fastest. Technological advancements, combined with the increasing prevalence of chronic diseases and organ failure, are boosting demand for artificial organs. This market segment is likely to increase significantly in the coming years as researchers continue to create revolutionary organ replacement alternatives.

Artificial Organ And Bionic Implants Market, By Application

Cardiovascular Implants

Orthopedic Implants

Neurological Implants

Ophthalmic Implants

Organ Transplants

Based on Application, the market is segmented into Cardiovascular Implants, Orthopedic Implants, Neurological Implants, Ophthalmic Implants, and Organ Transplants. Orthopedic implants now control the artificial organ and bionic implants market due to their widespread usage in joint replacement and fracture healing, but neurological implants are growing the fastest. Advances in neuroscience and neurotechnology, together with the rising prevalence of neurological illnesses, are boosting demand for neurological implants. These devices provide potential remedies for illnesses such as Parkinson's disease, epilepsy, and spinal cord injuries, resulting in a fast-developing market segment.

Artificial Organ And Bionic Implants Market, By End-User

Hospitals and Clinics

Research and Academic Institutes

Based on End-User, the market is segmented into Hospitals and Clinics and Research and Academic Institutes. Hospitals and clinics currently lead the artificial organ and bionic implants market due to their direct participation in patient care and surgical procedures, while research and academic institutes are expanding the fastest. These organizations play an important role in pushing innovation, conducting research, and developing new technologies in the fields of artificial organs and bionic implants. Increased investments in research & development, combined with cooperation between academia and industry, are driving the segment's growth and contributing to field breakthroughs.

Artificial Organ And Bionic Implants Market, By Geography

North America

Europe

Asia Pacific

Rest of the World

On the basis of Geography, the Global Artificial Organ And Bionic Implants Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America currently dominates the artificial organ and bionic implants market due to its well-established healthcare infrastructure and superior research capabilities; The Asia-Pacific region is rapidly growing in the market. This expansion is being driven by a fast-growing population, rising healthcare expenditure, and growing knowledge of the benefits of new technology. The region is seeing major expenditures in healthcare infrastructure and research, which are projected to fuel market growth.

Key Players

The "Global Artificial Organ And Bionic Implants Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Medtronic, Johnson & Johnson, Siemens Healthineers, Stryker Corporation, Zimmer Biomet, B. Braun Melsungen, Edwards Lifesciences, Boston Scientific, and Organovo, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Artificial Organ And Bionic Implants Market Recent Developments
• In August 2022, the American Society of Nephrology and the United States Department of Health and Human Services announced a new prize competition for the Kidney Innovation Accelerator at USD 10.5 Million. Phase 2 of the Artificial Kidney Prize competition seeks suggestions for developing prototype bioartificial kidneys, as well as any unique equipment or parts that would enable them.
• In January 2022, IIT-Kanpur initiated a project to create an advanced artificial heart. This initiative was developed in partnership with a few Indian hospitals and will be led by a team of innovators with relevant experience chosen under the mentoring of industry professionals.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Artificial Organ And Bionic Implants Market, By Type of Implant

• Artificial Organs
• Bionic Implants

5. Artificial Organ And Bionic Implants Market, By Application

• Cardiovascular Implants
• Orthopedic Implants
• Neurological Implants
• Ophthalmic Implants
• Organ Transplants

6. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

7. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

8. Competitive Landscape

• Key Players
• Market Share Analysis

9. Company Profiles

• Abbott Laboratories
• Medtronic
• Johnson & Johnson
• Siemens Healthineers
• Stryker Corporation
• Zimmer Biomet
• B. Braun Melsungen
• Edwards Lifesciences
• Boston Scientific
• Organovo Inc.

10. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

11. Appendix

• List of Abbreviations
• Sources and References